Literature DB >> 17094378

Down-regulation of RUNX1, RUNX3 and CBFbeta in hepatocellular carcinomas in an early stage of hepatocarcinogenesis.

Kouji Miyagawa1, Chouhei Sakakura, Susumu Nakashima, Tetsuji Yoshikawa, Shuichi Kin, Yuenn Nakase, Kosei Ito, Hisakazu Yamagishi, Hiroshi Ida, Shujiro Yazumi, Tsutomu Chiba, Yoshiaki Ito, Akeo Hagiwara.   

Abstract

BACKGROUND: Our previous studies suggested that deficient function of RUNX3 protein is causally related to development and progression of human gastric cancer. RUNX3 is mapped to 1p36, which is frequently deleted in hepatocellular carcinomas (HCC), therefore, these tumors were investigated for expression and copy number changes of RUNX3 and other Runt-related genes, RUNX1, RUNX2, and their co-factor CBFP. Similarly nearby uninvolved liver showing cirrhosis or normal histology was investigated in conjunction with various clinicopathological factors.
MATERIALS AND METHODS: Copy number change and expression change of RUNX family genes in 35 hepatocellular carcinoma specimens and adjoining liver with cirrhosis (LC) or normal histology were estimated using quantitative reverse transcription polymerase chain reaction (RT-PCR) and in situ hybridization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094378

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

Review 1.  Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics.

Authors:  Faisal Saeed Khan; Ijaz Ali; Ume Kalsoom Afridi; Muhammad Ishtiaq; Rashid Mehmood
Journal:  Hepatol Int       Date:  2016-06-07       Impact factor: 6.047

2.  Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy.

Authors:  Justin L Sewell; Kristine M Stick; Alexander Monto
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-02       Impact factor: 2.566

3.  Runx1 is a co-activator with FOXO3 to mediate transforming growth factor beta (TGFbeta)-induced Bim transcription in hepatic cells.

Authors:  Gary M Wildey; Philip H Howe
Journal:  J Biol Chem       Date:  2009-06-03       Impact factor: 5.157

Review 4.  Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma.

Authors:  Yuewu Yang; Zhiqiang Ye; Zengcheng Zou; Gemin Xiao; Gangjian Luo; Hongzhi Yang
Journal:  Tumour Biol       Date:  2014-07-19

5.  Promoter hypermethylation-mediated down-regulation of RUNX3 gene in human brain tumors.

Authors:  C B Avci; Y Dodurga; S Y Susluer; Z O D Sıgva; M Yucebas; H O Caglar; T Akalin; T Dalbasti; N Oktar; C Gunduz
Journal:  Ir J Med Sci       Date:  2013-08-11       Impact factor: 1.568

6.  Increased expression of RUNX1 in clear cell renal cell carcinoma predicts poor prognosis.

Authors:  Yang Fu; Shanshan Sun; Xiaojun Man; Chuize Kong
Journal:  PeerJ       Date:  2019-10-02       Impact factor: 2.984

7.  A Gene Signature of Survival Prediction for Kidney Renal Cell Carcinoma by Multi-Omic Data Analysis.

Authors:  Fuyan Hu; Wenying Zeng; Xiaoping Liu
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

Review 8.  Human hepatocyte carcinogenesis (review).

Authors:  Hidenori Shiraha; Kazuhide Yamamoto; Masayoshi Namba
Journal:  Int J Oncol       Date:  2013-02-19       Impact factor: 5.650

9.  Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer.

Authors:  H Kayed; X Jiang; S Keleg; R Jesnowski; T Giese; M R Berger; I Esposito; M Löhr; H Friess; J Kleeff
Journal:  Br J Cancer       Date:  2007-09-18       Impact factor: 7.640

Review 10.  The Multiple Roles of Hepatitis B Virus X Protein (HBx) Dysregulated MicroRNA in Hepatitis B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) and Immune Pathways.

Authors:  Kurt Sartorius; Leo Swadling; Ping An; Julia Makarova; Cheryl Winkler; Anil Chuturgoon; Anna Kramvis
Journal:  Viruses       Date:  2020-07-10       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.